Urinary and peritoneal acyclovir recovery
Stathoulopoulou 2002 — illustrative sensitivity analysis, not patient-matched validation.
Published endpoints
After one 500 mg oral valacyclovir dose, mean 24-hour urinary recovery was 3.4% in four participants with urine output. Mean CAPD recovery was 6.51% across eight participants. These means describe different participant subsets.
The reported denominator is ambiguous: 500 mg tablet mass versus 347.18 mg equimolar acyclovir. Under these interpretations, urinary recovery is 17.00 or 11.80 mg, and CAPD recovery is 32.55 or 22.60 mg. Both are retained; neither interpretation is selected as established.
Model sensitivity
Illustrative weights 50–90 kg and constant CrCl 0–10 mL/min; one 500 mg dose, bioavailability 0.545, four six-hour 2 L CAPD exchanges with 2.5% glucose and default transport coefficients. Published individual weights, kidney function and exchange prescriptions are unavailable. Endpoint includes the fourth drain. All results use default parameters without fitting.
| Weight (kg) | CrCl (mL/min) | Urine (mg) | Drained CAPD (mg) | Urine / tablet mass (%) | CAPD / tablet mass (%) | Urine / ACV equivalent (%) | CAPD / ACV equivalent (%) |
|---|---|---|---|---|---|---|---|
| 50.00 | 0.00 | 0.00 | 17.80 | 0.00 | 3.56 | 0.00 | 5.13 |
| 50.00 | 0.50 | 6.06 | 17.37 | 1.21 | 3.47 | 1.75 | 5.00 |
| 50.00 | 1.00 | 11.85 | 16.96 | 2.37 | 3.39 | 3.41 | 4.88 |
| 50.00 | 2.00 | 22.66 | 16.17 | 4.53 | 3.23 | 6.53 | 4.66 |
| 50.00 | 5.00 | 49.85 | 14.13 | 9.97 | 2.83 | 14.36 | 4.07 |
| 50.00 | 10.00 | 82.23 | 11.52 | 16.45 | 2.30 | 23.69 | 3.32 |
| 70.00 | 0.00 | 0.00 | 13.44 | 0.00 | 2.69 | 0.00 | 3.87 |
| 70.00 | 0.50 | 5.89 | 13.13 | 1.18 | 2.63 | 1.70 | 3.78 |
| 70.00 | 1.00 | 11.52 | 12.83 | 2.30 | 2.57 | 3.32 | 3.70 |
| 70.00 | 2.00 | 22.07 | 12.26 | 4.41 | 2.45 | 6.36 | 3.53 |
| 70.00 | 5.00 | 48.80 | 10.77 | 9.76 | 2.15 | 14.06 | 3.10 |
| 70.00 | 10.00 | 81.05 | 8.85 | 16.21 | 1.77 | 23.34 | 2.55 |
| 90.00 | 0.00 | 0.00 | 10.84 | 0.00 | 2.17 | 0.00 | 3.12 |
| 90.00 | 0.50 | 5.73 | 10.60 | 1.15 | 2.12 | 1.65 | 3.05 |
| 90.00 | 1.00 | 11.23 | 10.37 | 2.25 | 2.07 | 3.23 | 2.99 |
| 90.00 | 2.00 | 21.54 | 9.93 | 4.31 | 1.99 | 6.21 | 2.86 |
| 90.00 | 5.00 | 47.83 | 8.76 | 9.57 | 1.75 | 13.78 | 2.52 |
| 90.00 | 10.00 | 79.88 | 7.24 | 15.98 | 1.45 | 23.01 | 2.08 |
CAPD recovery falls below the reported group mean throughout this grid under either denominator interpretation. Urinary recovery crosses the mean under some assumptions; this does not identify actual participant kidney function. Amounts are excluded from the concentration figure and all pooled concentration metrics.
Reproduce with node research/validation/stathoulopoulou-capd.cjs. The script checks mass balance and integration-step convergence. This table is a fixed snapshot of that calculation.
Stathoulopoulou F et al. Evaluation of Valaciclovir Dosage Reduction in Continuous Ambulatory Peritoneal Dialysis Patients. Nephron. 2002;91:164–166. doi:10.1159/000057621